Tang Prize Award
Lecture — Saturday, April 6, 2019 — 6:00 PM - 7:00 PM — Convention Center, Room
Tang Foundation — Chair: Brian Druker — Co-Chair:
Abl is a tyrosine kinase, the gene of which upon translocation to a different chromosomal site (Bcr [breakpoint cluster region]) becomes constitutively active. In addition to Abl, Gleevec also inhibits Kit, PDGF and other tyrosine kinase oncoproteins. It has been useful in the treatment of acute lymphocytic leukemia (ALL) and certain types of gastrointestinal stromal tumors (GISTs) where Kit is overexpressed. Now there are more than 29 TKIs which have been approved for clinical use. Clearly, Dr. Druker’s first successful trials heralded this still burgeoning targeted therapy era. Dr. Druker was also involved in the development of the 4G10 antibody (at Thomas Robert’s lab) which recognizes phosphotyrosine and was used by Novartis colleagues in the screening of Gleevec. Thus, Dr. Druker’s contributions are in both the development and application of Gleevec, which was the first successful example of tyrosine kinase-targeted therapy by small molecule inhibitors.
- Imatinib as a Paradigm of Targeted Cancer Therapies
Brian Druker — Knight Cancer Inst., Oregon Hlth. & Sci. Univ.